Migraine Prevention Drug Pipeline — PatSnap Eureka
Migraine Prevention Drug Pipeline: CGRP Antibodies, Gepants & Novel Targets
Over one billion people live with migraine globally. The CGRP pathway has become the dominant validated target for migraine-specific preventive therapies, driving a wave of biologic and small molecule innovation from Amgen, Teva, Eli Lilly, Biohaven, and emerging challengers.
Four Major Modalities Targeting the CGRP Pathway
From injectable biologics to oral small molecules, gene therapy, and next-generation neuropeptide targets — the migraine prevention pipeline spans a broad innovation spectrum.
Anti-CGRP & Anti-CGRP Receptor Monoclonal Antibodies
The dominant modality in this dataset. Four named programs — erenumab (Amgen/Novartis, anti-receptor), fremanezumab (Teva, anti-ligand), galcanezumab (Eli Lilly, anti-ligand), and eptinezumab (H. Lundbeck A/S, anti-ligand) — collectively cover monthly subcutaneous and intravenous administration. Amgen's patents specify full CDR sequences anchoring broad IP claims across at least 9 jurisdictions. Phase 3 RCT data (EVOLVE-1, EVOLVE-2, REGAIN) are referenced in the dataset for galcanezumab.
9 jurisdictions · Amgen estateCGRP Receptor Antagonist Gepants
Oral small molecule CGRP receptor antagonists — rimegepant (Biohaven), atogepant and ubrogepant (Allergan/AbbVie) — are positioned for both acute and preventive use. Rimegepant's dual utility as an acute and preventive agent is explicitly claimed in retrieved filings. Brise Pharmaceuticals filed patents through 2025 for structurally distinct piperidine carboxamide azaindane derivatives including deuterated variants, signaling active next-generation scaffold diversification outside established Western biopharma.
Oral · Dual acute/preventiverAAV-Vectorized Anti-CGRP Antibody Delivery
RegenxBio filed a WO patent in 2022 describing recombinant AAV-based delivery of fully human, post-translationally modified anti-CGRP and anti-CGRP receptor monoclonal antibodies. Dual transgene constructs encoding both binding moieties are described. This approach is designed as a long-acting, single-administration alternative to monthly mAb injections, targeting adherence challenges. This modality is at a preclinical/early translational stage based on retrieved data.
Preclinical · Single-dose conceptAnti-PACAP/PAC1 Antibodies for CGRP Non-Responders
CGRP Diagnostics GmbH (WO 2023) and independent inventor Hasleton (WO 2024) describe anti-PACAP and anti-PAC1 antibody approaches as complementary or alternative strategies for patients inadequately responding to anti-CGRP therapy. Anti-PAC1 antibodies are noted to act peripherally, binding the trigeminal ganglion and sphenopalatine ganglion without significant CNS penetration. These filings represent the leading edge of beyond-CGRP target biology in this dataset.
2023–2024 filings · Early-stageWhy CGRP Became the Dominant Migraine Target
CGRP is a 37-amino acid neuropeptide belonging to a peptide family that includes calcitonin, adrenomedullin, adrenomedullin 2 (intermedin), and amylin. Two human isoforms — α-CGRP and β-CGRP — differ by three amino acids and exhibit differential tissue distribution. At least two CGRP receptor subtypes with differential activities have been characterized.
The mechanistic case for targeting CGRP is well-established: jugular venous levels of CGRP are elevated during migraine attacks, and intravenous CGRP infusion reproducibly induces migraine-like headache in susceptible individuals. The CGRP receptor is a multicomponent complex comprising a seven-transmembrane domain protein, receptor activity-modifying protein (RAMP1), and receptor component protein (RCP), with signaling routed through adenylate cyclase and cAMP production.
Patent filings from leading IP analytics show Teva Pharmaceuticals, Amgen, and H. Lundbeck A/S all anchor claims to the peripheral and central roles of CGRP: vasodilation, neurogenic inflammation, protein extravasation at the meningeal level, and sensitization in the trigeminal ganglion. According to WHO, migraine is one of the leading causes of years lived with disability worldwide, underscoring the therapeutic urgency driving this IP activity.
A secondary target emerging in retrieved results is PACAP (pituitary adenylate cyclase-activating peptide) and its PAC1 receptor, described as a complementary approach particularly for patients inadequately responding to CGRP-directed agents. A third target, the insulin-like growth factor receptor (IGFR) pathway, is proposed by Seurat Therapeutics in combination with CGRP inhibitors for migraine and post-traumatic headache.
Key Assignees & Modality Distribution
Patent filing concentration and therapeutic modality spread derived from PatSnap Eureka analysis of the migraine prevention pipeline dataset.
Key Assignees by Jurisdiction Coverage
Amgen leads with 9 jurisdictions for anti-CGRP receptor antibody claims; Teva and Lundbeck each cover 7 jurisdictions with active and pending filings through 2025–2026.
Pipeline Modality Distribution
Anti-CGRP mAbs dominate the IP landscape in this dataset, with gepants representing active diversification and novel targets (PACAP/PAC1, gene therapy) forming the emerging frontier.
Who Holds the IP in Migraine Prevention?
Patent activity is strongly concentrated among a small number of commercial assignees, with academic literature providing clinical context and translational data.
Assess Freedom-to-Operate Across CGRP Modalities
IP saturation in the core CGRP mAb space is high. Use PatSnap Eureka to map claim scope and identify white space.
Seven Emerging Directions in the Migraine Pipeline
Combination regimens are a clear strategic focus: retrieved results document three distinct IP-protected combination strategies, all filed by major commercial assignees.
Gepant + mAb: Dual CGRP Blockade
The Phase 1b ubrogepant pharmacokinetics study (AbbVie, 2021) and Biohaven's dual-treatment patent (WO, 2022) both support co-administration of oral CGRP receptor antagonists for acute breakthrough attacks in patients receiving preventive anti-CGRP mAbs. The AbbVie PK study found mAb co-administration did not substantially alter ubrogepant exposure, supporting pharmacological compatibility.
CGRP Antagonist + Lasmiditan
Eli Lilly's patents in AU and IL (2020) claim combinations of galcanezumab with lasmiditan — a selective 5-HT1F receptor agonist — for therapy-resistant migraine refractory to two or more prior treatment regimens. This signals interest in targeting both the CGRP pathway and the serotonergic 5-HT1F receptor simultaneously.
CGRP Antagonist + Botulinum Toxin
Allergan's CA patent (2020) claims combination of gepants with botulinum toxin (clostridial derivatives) for migraine and headache, addressing chronic migraine patients with overlapping indications for both agents.
CGRP Inhibitor + IGF-1/IGFR Activator
Seurat Therapeutics' patents (CA 2021, AU 2022) propose combining anti-CGRP agents with insulin-like growth factor-1 or IGFR activators for migraine, post-traumatic headache, and fibromyalgia. This combination targets upstream neuronal sensitization mechanisms distinct from CGRP pathway blockade. Evidence for this approach is patent-only and appears early-stage.
From Patents to Phase 3: Clinical Evidence in the Dataset
The dataset contains several explicit clinical signals. Phase 3 randomized controlled trial data for galcanezumab are referenced in a 2020 academic paper (Eli Lilly author affiliation) describing EVOLVE-1, EVOLVE-2 (episodic migraine, 6-month, pooled), and REGAIN (chronic migraine, 3-month) trials, with subcutaneous galcanezumab 120 mg monthly versus placebo, evaluating a composite total pain burden metric (severity-weighted frequency × duration).
Phase 1b drug-drug interaction study data are referenced in a 2021 paper (AbbVie affiliation) evaluating ubrogepant pharmacokinetics when co-administered with erenumab and galcanezumab in a multicenter, open-label, randomized design — direct translational evidence supporting combination use of gepants with mAbs. According to NIH, combination pharmacology studies are increasingly central to modern migraine drug development.
Real-world observational study data are referenced in a 2021 paper (Evidera affiliation) from the ATTAIN study, characterizing migraine preventive treatment patterns in episodic and chronic migraine patients initiating treatment before CGRP inhibitor introduction (March 2016–October 2017), establishing baseline burden and unmet need. The PatSnap Life Sciences platform provides deeper access to this clinical evidence layer alongside patent data.
Patient population stratification for clinical use is addressed in multiple patents: Teva's refractory migraine filings specify patients with ≥2 migraine attacks per month or severely impaired quality of life; Eli Lilly's treatment-resistant patent covers prior inadequate efficacy, safety failure, or tolerability failure; Lundbeck's most bothersome symptom (MBS) patent specifies improvement within 1 month; CGRP Diagnostics GmbH's filings focus on patients without allodynia/hyperalgesia in the post-ictal phase as a responder-selection criterion. Learn more about biomarker-driven patient stratification approaches at EMBL-EBI.
Importantly, no retrieved results contain evidence of anti-PACAP, anti-PAC1, IGF-1/IGFR, or vectorized AAV gene therapy clinical trial data — these are represented only by preclinical or mechanistic patent claims.
What the IP Landscape Means for Developers & Investors
Five strategic signals from the migraine prevention patent dataset, relevant to new entrants, established players, and investors evaluating the space.
Core CGRP mAb Space Is Highly IP-Dense
IP saturation in the core CGRP mAb space is high in this dataset, with Amgen, Teva, Eli Lilly, and Lundbeck holding broad and geographically distributed active patents. New entrants to the mAb modality face significant freedom-to-operate constraints. Differentiation via patient subpopulation claims, dosing regimen innovations, and indication expansion appears to be the primary IP strategy for incumbents. Use PatSnap Analytics to assess FTO risk.
High barrier for new mAb entrantsGepant Space Shows Active Scaffold Diversification
The gepant small molecule space shows active diversification, with Biohaven (rimegepant), Allergan/AbbVie (atogepant, ubrogepant), and Brise Pharmaceuticals (azaindane deuterated scaffolds, 2025 filings) all prosecuting patents. The dual acute/preventive utility of rimegepant — explicitly claimed in retrieved filings — represents differentiated commercial positioning relative to injectable mAbs. Explore the PatSnap chemicals and materials platform for scaffold analysis.
Next-gen gepant chemistry emergingCombination Patents Are a Barrier-to-Entry Mechanism
Combination regimens are a clear strategic focus: retrieved results document three distinct IP-protected combination strategies (gepant + mAb, CGRP antagonist + lasmiditan, CGRP antagonist + botulinum toxin), all filed by major commercial assignees. Developers should monitor combination patent grants as potential barrier-to-entry mechanisms in the refractory migraine submarket. According to EPO guidance, combination therapy claims require careful prior art analysis.
3 documented IP-protected combosPACAP/PAC1 & Gene Therapy Are Clear White-Space Opportunities
PACAP/PAC1 and gene therapy vectorization represent the clearest white-space opportunities in this dataset, with minimal competing filings, early-stage evidence, and explicit positioning as solutions for CGRP non-responders. Investors and developers evaluating next-generation migraine prevention should assess preclinical programs in these modalities. The PatSnap customer success stories include multiple examples of white-space identification in neurology.
Minimal competing filings (2023–2024)Biomarker-Driven Patient Selection Is an Emerging IP Battleground
Patient stratification and precision medicine are emerging IP and clinical themes: filings from CGRP Diagnostics GmbH, Beth Israel Deaconess Medical Center, and Eli Lilly all claim patient-selection methods (allodynia status, hyperalgesia, prior treatment failure criteria) as components of patentable therapeutic methods. Biomarker-driven responder identification may become a key IP battleground as the field matures beyond population-level efficacy claims.
Allodynia · Hyperalgesia · Prior failure criteriaPsychiatric Comorbidity as a New Therapeutic Frontier
H. Lundbeck A/S's WO and US filings (2025–2026, pending) claim methods for treating depressive symptoms and psychiatric disorders with anti-CGRP antagonist antibodies, representing an indication expansion beyond pain endpoints into comorbid neuropsychiatric territory. This signals that the CGRP antibody IP estate is being extended well beyond the core migraine prevention indication.
Lundbeck 2025–2026 pending filingsMigraine Prevention Drug Pipeline — key questions answered
CGRP (calcitonin gene-related peptide) is the central molecular driver of migraine pathophysiology and the dominant validated target in the current pipeline. Jugular venous levels of CGRP are elevated during migraine attacks, and intravenous CGRP infusion reproducibly induces migraine-like headache in susceptible individuals. Both monoclonal antibodies and small molecule gepants target this pathway.
The four named anti-CGRP monoclonal antibody programs are: erenumab (Amgen/Novartis, anti-CGRP receptor), fremanezumab (Teva, anti-CGRP ligand), galcanezumab (Eli Lilly, anti-CGRP ligand), and eptinezumab (Alder Biopharmaceuticals/H. Lundbeck A/S, anti-CGRP ligand).
Gepants are oral small molecule CGRP receptor antagonists used for both acute and preventive migraine treatment. Named compounds include rimegepant (Biohaven), atogepant (Allergan/AbbVie), and ubrogepant (Allergan/AbbVie). Unlike injectable monoclonal antibodies administered monthly, gepants can be taken orally on a daily or as-needed basis, and rimegepant has demonstrated dual utility for both acute breakthrough attacks and prevention.
Beyond CGRP, the emerging targets include: PACAP (pituitary adenylate cyclase-activating peptide) and its PAC1 receptor, with anti-PACAP and anti-PAC1 antibodies positioned for patients inadequately responding to anti-CGRP therapy; the IGFR/IGF-1 pathway, proposed by Seurat Therapeutics in combination with CGRP inhibitors; and the serotonin 5-HT1F receptor targeted by lasmiditan, being studied in combination with galcanezumab for therapy-resistant migraine.
Retrieved results document multiple IP-protected combination strategies: gepant + anti-CGRP mAb (dual CGRP blockade for breakthrough migraine); CGRP antagonist + lasmiditan (dual-mechanism targeting CGRP and 5-HT1F pathways); CGRP antagonist + botulinum toxin (Allergan); CGRP inhibitor + IGF-1/IGFR activator (Seurat Therapeutics); and rAAV gene therapy delivering anti-CGRP antibodies as a long-acting single-administration alternative (RegenxBio).
RegenxBio filed a WO patent in 2022 describing rAAV-based gene therapy delivery of anti-CGRP or anti-CGRP receptor monoclonal antibodies for treatment and prevention of migraine and cluster headaches. The approach involves delivery of fully human, post-translationally modified mAbs via recombinant AAV vectors, including dual transgene constructs encoding both anti-CGRP and anti-CGRP receptor binding moieties. This modality is at a preclinical/early translational stage based on retrieved data.
Still have questions? Let PatSnap Eureka search the migraine patent literature for you.
Ask PatSnap Eureka About Migraine IPAccelerate Your Migraine Pipeline Research with AI-Powered Patent Intelligence
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D. Search CGRP, gepant, PACAP, and gene therapy patents in one workspace.
References
- CGRP Antagonists for Treating Migraine Breakthrough — Biohaven Pharmaceutical Holding Company Ltd., 2020, WO [Patent]
- CGRP Antagonists for Treating Migraine Breakthrough — Biohaven Pharmaceutical Holding Company Ltd., 2020, CA [Patent]
- Human CGRP Receptor Binding Antibodies — Amgen, Inc., 2018, RS [Patent]
- Methods for Treating or Preventing Migraine Headache — Amgen Inc., 2016, US [Patent]
- Methods for Treating or Preventing Migraine Headache — Amgen Inc., 2022, US [Patent]
- Methods for Treating or Preventing Migraine Headache Using Antibodies Directed at the CGRP Receptor — Amgen, Inc., 2024, EP [Patent]
- Methods for Treating or Preventing Migraine Headache Using Antibodies Directed at the CGRP Receptor — Amgen, Inc., 2020, EP [Patent]
- Treating Refractory Migraine — Teva Pharmaceuticals International GmbH, 2019, EP [Patent]
- Treating Refractory Migraine — Teva Pharmaceuticals International GmbH, 2023, US [Patent]
- Treating Refractory Migraine — Teva Pharmaceuticals International GmbH, 2024, US [Patent]
- Treating Refractory Migraine — Teva Pharmaceuticals International GmbH, 2025, US [Patent]
- Anti-CGRP Antibodies for Treatment-Resistant Patients — Eli Lilly and Company, 2020, WO [Patent]
- Dual Treatment of Migraine — Biohaven Pharmaceutical Ireland DAC, 2022, WO [Patent]
- Treatment of Migraine — Allergan Pharmaceuticals International Limited, 2019, US [Patent]
- Combination Therapy with CGRP Antagonists and Clostridial Derivatives — Allergan Pharmaceuticals International Limited, 2020, CA [Patent]
- Piperidine Carboxamide Azaindane Derivative, Method for Preparing Same, and Use Thereof — Brise Pharmaceuticals Co., Ltd., 2025, US/EP [Patent]
- Vectorized Anti-CGRP and Anti-CGRPR Antibodies and Administration Thereof — RegenxBio Inc., 2022, WO [Patent]
- Preventative Treatment of Migraine — CGRP Diagnostics GmbH, 2023, WO [Patent]
- Treatment of Migraine — Hasleton, Mark, 2024, WO [Patent]
- Acute Treatment and Rapid Treatment of Headache Using Anti-CGRP Antibodies — H. Lundbeck A/S, 2025, US [Patent]
- Treatment of Headache Disorders and/or Psychiatric Symptoms Using Anti-CGRP Antibodies — H. Lundbeck A/S, 2025, WO [Patent]
- Impact of Galcanezumab on Total Pain Burden: EVOLVE-1, EVOLVE-2, and REGAIN Trials — Eli Lilly and Company, 2020 [Paper]
- Pharmacokinetics and Safety of Ubrogepant When Coadministered with CGRP-Targeted Monoclonal Antibody Migraine Preventives — AbbVie, 2021 [Paper]
- Reducing the Burden of Migraine: Safety and Efficacy of CGRP Pathway-Targeted Preventive Treatments — Teva Branded Pharmaceutical Products R&D, Inc., 2022 [Paper]
- World Health Organization — Headache Disorders Fact Sheet
- National Institutes of Health — CGRP and Migraine Research
- European Patent Office — Combination Therapy Patent Guidance
- EMBL-EBI — Biomarker and Patient Stratification Resources
- NCBI PubMed — RAMP1 and CGRP Receptor Biology
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.